Neurology Central

Translating blood biomarkers into the clinic for neurodegenerative diseases with Henrik Zetterberg

Tremendous efforts have been made in the last few years with regards to blood biomarkers for neurodegenerative diseases. From the discovery of serum neurofilament light as a sensitive biomarker for neuronal loss to advancements in imaging techniques, the field is moving forward at an extremely quick pace.

In this video interview, we spoke with Henrik Zetterberg at the Wolfson Closing Symposium on Intervening in Neurodegeneration (19 June 2019, University College London, UK) to find out more about the current status of the field. Henrik spoke to us about how the challenges surrounding replication and reproducibility might be addressed, in addition to discussing the issues around specificity with serum neurofilament light. Take a look at our questions below and watch the video to hear his responses.


00:05 – Please could you introduce yourself and tell us about your current research focuses?

00:22 – Can you tell us about some of the most promising new areas of research in the search for blood biomarkers for the pre-clinical phase of Alzheimer’s disease?

01:36 – One of the biggest challenges surrounding blood-based biomarkers for neurodegenerative disease is the lack of replication and reproducibility. What could be done to overcome these obstacles?

03:19 – In relation to serum neurofilament light, how might the challenge of specificity be addressed?

04:51 – What further steps are required for the clinical translation of blood-based biomarkers?

You might also like: